The agreement grants exclusive rights to Weigao Orthopedic for the sale, marketing and distribution of Misonix’s novel surgical device named BoneScalpel in China, Hong Kong, and Macau for an initial period of five years.
BoneScalpel is a unique surgical device that offers a gentler osteotomy as compared to standard bone-cutting tools.
Biotech company, Thermo Fisher Scientific, intends to raise gross proceeds of €500m ($529.99m) through a public offering of 1.45% senior notes due 16 March 2017.
The notes, which will raise net proceeds of approximately €492.12m ($521.63m), will be issued at 98.824% of the principal amount and will yield 1.578% upon maturity.
A portion of the proceeds will be used to redeem the company’s outstanding $500m aggregate principal amount of its 1.85% senior notes due 2018, while the remaining will be used for general corporate purposes.
Blugrass will also fund Merit Medical’s efforts to secure FDA clearance for sale of the product in the US, as part of the contract.
The Surfacer system, which received CE mark approval in the European Union in August 2016, is an inside-out approach to restore access to the right internal jugular (RIJ) vein and to preserve treatment options in haemodialysis patients with occluded veins.
Cerveau Technologies and Wisconsin Alzheimer’s Disease Research Center have entered a clinical research agreement to support a number of research projects conducted at the centre to study the stages of Alzheimer’s disease and other neurodegenerative diseases.
Under the agreement, Cerveau will supply an early-stage imaging agent (MK-6240) to the centre for use in Positron Emission Tomography (PET) scans that assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
The collaboration will provide key data about the rates of progression across the Alzheimer’s disease stages, from pre-clinical to overt dementia.
Noventure, a start-up company specialising in licensing medical devices, has partnered with European specialist pharmaceutical company, Norgine, for the distribution of the former’s Class IIa CE-marked medical device, Gelsectan, in Spain, Portugal and Andorra.
Gelsectan, which is anticipated to be launched in Iberia, Europe, in the second half of 2017, is a device used for the treatment of patients with irritable bowel syndrome (IBS) associated with diarrhoea.